All posts by medical

Adaptive tuning of cell sensory diversity without changes in gene expression – Science Advances

INTRODUCTION

A central question in cell biology is how a population of cells deals with an ever-changing environment. A canonical paradigm for cellular responses to environmental challenges is the genetic switch, perhaps best exemplified by the lac operon (1), where cells sense changes in environmental factors and respond by changing gene expression. The response time scale of this strategy is limited by that of transcription and translation (~1 hour), leaving cells vulnerable to rapid fluctuations in the environment. A contrasting strategy that allows cells to cope with uncertain or rapidly changing environments is bet hedging, where cell populations diversify their phenotypes even within stable environments, by exploiting inherent stochasticity in cellular processes (26). Bet hedging allows subpopulations of cells to be prepared in advance, by maintaining a heterogeneous distribution of phenotypes matched to the repertoire of environments they might encounter in the future. Although genetic switching and bet hedging provide contrasting survival strategies with distinct advantages, they are not mechanistically exclusive. Bacteria can control the degree of phenotypic diversity in an environment-dependent manner by dynamically modulating gene expression noise (79). Here, we demonstrate that cells can modulate their phenotypic diversity even in the absence of gene expression changes through posttranslational processes, thus implementing fast control of phenotypic diversity.

The chemotaxis signaling pathway of Escherichia coli detects and responds to temporal changes in the extracellular concentrations of chemoeffector molecules through receptor-kinase complexes consisting of thousands of interacting two-state chemoreceptor proteins and kinases (6, 10). An adaptation mechanism, mediated by methylation and demethylation of the chemoreceptors, modulates the sensitivity of the system. Like in many other sensory systems in biology (1113), bacteria respond to relative changes in the signal (14), thus following the Weber-Fechners law of psychophysics (1517) and fold-change detection (FCD) (18, 19). The wealth of quantitative data that has been collected for this system through population-averaged measurements (14, 2023) provides a powerful foundation for examining how individual cells differ from the average in their sensory response and whether and how such diversity is modified upon adaptation.

To quantify the sensitivity of individual cells in the presence of different background-stimulus levels, we combined single-cell fluorescence resonance energy transfer (FRET) measurements of the chemotaxis signaling activity (24, 25) with a microfluidic system for fast stimulus modulation. We found that in the absence of any background signal, the individual cells sensitivities are distributed over about one decade of concentration, but upon adaptation to a background signal, the distribution of sensitivities narrows down to about one tenth of a decade, thus focusing the populations sensitivities to the relevant signal range. Combining experiments and mathematical analyses, we show how the population of cells exploits a standing variation in the degree of allosteric receptor coupling and the environment-dependent covalent modification of the receptors to tune the diversity in signaling sensitivities, which emerges in a class of allosteric models of two-state receptor activity. Crucially, this modulation of sensory diversity does not require any changes in the expression level of proteins, and hence, this mechanism can operate rapidly and in the absence of growth. Rather, it is a network-level property that arises through an adaptive change in the nonlinear mapping between molecular states and sensory phenotype.

To quantify the sensitivity of the chemotaxis system in individual E. coli cells, we stimulated them with short pulses of -methylaspartate (MeAsp)a nonmetabolizable analog of the chemoattractant aspartate (26)while monitoring the output of the signaling pathway using an in vivo single-cell FRET measurement of the activity of the kinase CheA (Fig. 1) (24, 25). To measure instantaneous responses of cells without confounding effects due to adaptation, we developed a polydimethylsiloxane (PDMS)based microfluidic device capable of fast (~0.1 s) switching between stimulus levels (see Materials and Methods, Fig. 1A, and fig. S1), nearly 100-fold faster than the cells adaptation time scale upon a small stimulus, which is on the order of 10 s (20). Cells grown to mid-exponential phase [optical density (OD) = 0.46 0.01] were washed in motility buffer and gently loaded in the device where they attached to the surface of the coverslip. We then subjected the cells to a sequence of eight identical subsaturating step stimuli presented over zero background while measuring the FRET level in each individual cell (~100 cells per experiment) (Fig. 1B). To avoid sampling highly correlated responses from a single cell due to the relatively slow temporal fluctuation in the kinase activity [correlation time ~12 s; (25)], measurements were conducted over >100 s with 15-s intervals between consecutive stimuli. A saturating step of MeAsp (>0.5 mM) was used to determine the FRET level corresponding to zero kinase activity at the beginning of each measurement (Fig. 1B). The FRET level after subtracting this zero-kinase level, hereafter called the FRET signal, is proportional to the kinase activity [see Materials and Methods; (21)].

(A) Fast and precise control of input stimuli within our bespoke microfluidic device. Top: Temporal profile of the ligand stimulus within the device, measured using a fluorescent dye. Our stimulus protocol involves one large stimulus followed by eight subsaturating step stimuli. Bottom: Superimposing multiple stimulus time series (each in a different color) demonstrates fast and highly reproducible relaxation for both steps up (left) and steps down (right). For a drawing and more details of the device, see fig. S1. (B) Responses are highly variable both across isogenic cells from the same growth culture and over time within the same cell. Response time series (FRET signal normalized by its steady-state level) for 5 representative cells out of the 133 measured in a single experiment are shown. Blue shading indicates times at which MeAsp step stimuli were applied (4 M, except the first stimulus, which was 0.5 mM). Gray circles indicate FRET response, and red lines indicate its moving average with a 1.5-s window. (C) Poststimulus activity is defined as the median FRET signal level (black line) during the 3-s step stimulus (blue shading) relative to the steady-state FRET level. (D) Summary of response variability upon 4 M MeAsp steps for all 133 cells measured in the experiment of (B). All responses (poststimulus activities) Ri (light gray) upon repeated application of identical steps are shown for every measured cell, sorted by rank of their median response R (dark gray). Note that Ri and R can take negative values due to measurement noise (fig. S2). The cumulative distribution of median response (traced out by the R point series) is broad, indicating extensive diversity across cells. a.u., arbitrary units.

The instantaneous response of a cell to a step stimulus was quantified by the poststimulus activity defined as the FRET signal relative to the steady state: Ri = Fi/Fss, where Fi is the median of the FRET signal over the 3 s during the ith step stimulus and Fss is the steady-state FRET signal, defined as the average over the entire time series except the time points during and right after the step stimuli (see Materials and Methods; Fig. 1C). The mean level of measurement noise for each individual response was 17% of the steady-state FRET signal (fig. S2), and the response distributions were stationary during the measurements (fig. S3). Sorting cells by their median poststimulus activity reveals substantial cell-to-cell variability (Fig. 1D), consistent with previous reports of phenotypic variability in this system (6, 25, 2730). Within each cell, we also observe large variations in the responses to identical stimuli (Fig. 1D, light gray dots), consistent with previous reports of temporal (behavioral) variability in individual cells adapted to a constant environment (6, 24, 25, 31). We ruled out cell cycle phase as a source of the cell-to-cell variation in kinase responses, as the latter demonstrated no correlation with cell length (fig. S4).

The standard method for determining the sensitivity of a signaling pathway is to fit the sigmoidal K1/2H/([L]H+K1/2H) to dose-response measurements and determine 1/K1/2 as the sensitivity of the cell. This approach has been used to quantify the dose response of populations of E. coli cells using FRET-based methods (21, 23, 32) and non-adapting single cells (25). However, this approach becomes impractical for measuring the response of single cells in the presence of adaptation because of the limited photon budget in single-cell FRET (25). Therefore, we devised an alternative strategy for determining the distribution of K1/2 within a cell population without the need to measure dose-response curves from individuals (Fig. 2).

(A) Principle of extracting the K1/2 distribution, p(K1/2), without dose-response measurements. K1/2, defined as the stimulus level that yields half-maximal poststimulus activity (R = 0.5), is typically determined by measuring dose-response curves (middle), which can vary from cell to cell. Here, we instead measure the distribution of R upon a stimulus of magnitude [L]j, p(R([L]j)), because the fraction of cells with K1/2 smaller than a given stimulus magnitude [L]j (p(K1/2 < [L]j); colored at the top) is equal to the fraction of cells whose poststimulus activity R([L]j) is less than one-half (p(R([L]j) < 0.5); colored at the bottom). (B) By repeating experiments of the type depicted in Fig. 1 at different stimulus step sizes [L]j, we build up the cumulative distribution of K1/2, p(K1/2 < [L]j). Each of the three panels on the left shows the summary of responses (as in Fig. 1D) for an experiment with a different [L]j (added MeAsp concentration, given in M by bold-faced numbers within panels), where sorting cells by their median poststimulus activity R (dark gray dots) provides the cumulative distribution of R, p(R([L]j) < r), corresponding to the fraction of cells whose response to [L]j is smaller than r (0 r 1). Using the identity illustrated in (A), the cumulative distribution of K1/2 (p(K1/2 < [L]j); rightmost) can be constructed by reading off values for p(R([L]j) < r) at r = 0.5 for each applied stimulus level [L]j. Error bars in the right show 95% bootstrap CIs.

To determine the distribution of K1/2, we exploited a simple identity relating the distribution of K1/2 to that of R, the (median) poststimulus activity of individual cells, which states that the fraction of cells with K1/2 smaller than a given stimulus magnitude [L] is equal to the fraction of cells whose (median) poststimulus activity R([L]) is less than one-half (Fig. 2A)p(K1/2<[L])=p(R([L])<0.5)(1)

Thus, from the distributions of the within-cell median poststimulus activities, one can construct the cumulative distribution function (CDF) of K1/2 of the population by determining, for each step stimulus intensity [L], the relative rank of the cell whose median poststimulus activity is 0.5 (Fig. 2B). Equation 1 is valid for any monotonic dependence of R on [L] and does not assume any specific steepness of a cells response curve or variation of it across cells.

Following this approach, we first determined the median of the poststimulus activity of individual cells adapted to a uniform environment with no MeAsp in the background, by stimulating cells with step stimuli that ranged from 0 to 30 M MeAsp (Fig. 3A). From these data, we extracted the distribution of K1/2 (inverse sensitivity), which was well approximated by a log-normal distribution (see Materials and Methods; Fig. 3, B and C). We found that in zero background, the sensitivity of individual cells to MeAsp was distributed over a wide range covering about one decade (~1 M < K1/2 < ~10 M).

(A) Summary of responses to step stimulation by MeAsp (gray dots: response to individual steps Ri, colored dots: median response of each cell R). Background concentration ([L]0) and step size ([L]) are shown in M at the top and within each panel, respectively. Cells are sorted by their median response. (B) Cumulative distribution of K1/2, p(K1/2 < [L]), of responses to MeAsp in cells adapted to three different background concentrations of MeAsp, [L]0 = {0,100,200} M, constructed from the data in (A) through the procedure outlined in Fig. 2. Curves represent fits by log-normal distributions. Error bars are 95% bootstrap CIs. The concentrations of stimuli used to define saturating responses are indicated by the triangles. (C) The distributions of K1/2 computed from the fits in (B) reveal that diversity in K1/2 is strongly attenuated upon adaptation to both 100 and 200 M MeAsp. Note that in this panel, the distribution at each background concentration is centered by normalizing K1/2 by the mode of the distribution to facilitate visual comparison. (D) Cumulative distribution of K1/2, p(K1/2 < [L]), of responses to serine in cells adapted to different background concentrations of serine, [L]0 = {0,1} M.

Given the well-characterized adaptation to ambient chemoattractant concentration at the population level, we wondered whether and how the single-cell distribution of sensitivities could be affected by adaptation to a constant nonzero background of MeAsp. Consistent with the population-level FRET measurements (14, 21), the average of the K1/2 distribution shifted with the background stimulus level due to sensory adaptation when cells were adapted to 100 M MeAsp before step stimulation (Fig. 3B). Unexpectedly, the diversity in response sensitivity across cells also changed drastically, with the K1/2 distribution becoming much narrower upon adaptation (Fig. 3C). A similar collapse in the K1/2 distribution width was found to occur for cells adapted to a higher (200 M) background of MeAsp. We further determined that this sensory diversity tuning is not specific to the MeAsp receptor Tar, as the distribution for serine, the cognate ligand of the other major chemoreceptor Tsr, demonstrated a similar collapse in width upon adaptation (Fig. 3D and fig. S5). Thus, the environment-dependent tuning of response diversity is not specific to a single receptor species and appears to be a general property of the bacterial chemotaxis network.

Recent studies have shown that cell populations can control the level of phenotypic diversity in an environment-dependent manner by modulating the variance of the protein abundance distributions (79). Here, by contrast, experiments were carried out under conditions in which neither the cognate receptors nor any other protein can be synthesized (due to auxotrophic limitation; see Materials and Methods). The observed tuning of sensory diversity must therefore be attributable to a mechanism that involves posttranslational processes rather than changes in gene expression.

To understand the molecular mechanism underlying this adaptive tuning of diversity in cell response sensitivities (Fig. 3), we turned to modeling. The receptor-kinase complexes of the chemotaxis system in E. coli and other species are arranged in hexagonal arrays of trimers of dimers that respond cooperatively to signals (33, 34). The activity of such clusters can be modeled using an extension of the Monod-Wyman-Changeux (MWC) model of allostery (35) and has been shown to agree with a large body of experimental data (20, 23, 3642). In this model (Fig. 4A and Supplementary Text), allosteric interactions between n coupled receptors form signaling teams within which all n receptors (and associated kinase molecules) share the same activity states (active or inactive). The free energy difference between the two receptor states is determined not only by the ligand concentration [L] (analogous to the oxygen concentration in the classical MWC model for hemoglobin) but also by the average methylation level m of receptors. Because of feedback from downstream adaptation enzymes, the value of m at steady state, in turn, depends on the background stimulus level [L]0, i.e., m = m([L]0). Kinase activity upon a step change in input from a given background [L]0 to another stimulus level [L] depends on two parameters n and m*, where m* is the receptor methylation level in the absence of ligand stimulus. Values of the parameters n and m* for E. coli chemoreceptors have been constrained by a large body of population FRET data (20, 21, 36, 37, 39, 42) and have been shown to vary as a function of expression level ratios between key chemotaxis signaling proteins (23, 25). Given that these ratios are affected by stochastic gene expression, the values of n and m* can vary across individual cells of the population (25), whereas values of other biochemical parameters (e.g., the dissociation constants of the receptors) are intrinsic to the structure of relevant proteins, which can be assumed invariant across isogenic populations of cells (see Supplementary Text).

(A) Schematic for allosteric MWC model of the receptor kinase complex. The effective number of coupled receptor dimers n affects the response of kinase activity a upon a step change in ligand concentration from [L]0 to [L], through the expression a = (1 + exp (f(n, m*, [L]0, [L])))1, where m* is the methylation level of the receptors in the absence of ligand. Both n and m* can vary across cells due to differences in gene expression. (B) Two limiting cases of cell-to-cell variation in the model parameters. Model 1 (red solid lines): m* is fixed, but n varies across cells. Model 2 (blue dotted lines): n is fixed, but m* varies across cells. (C to E) Fits of models 1 and 2 to the distribution of steady-state kinase activity a0 (C), population-averaged dose-response curves (D), and distribution of logK1/2 (E). Black corresponds [in (C) and (D)] to measured data and [in (E)] to probability density computed from model fits to cumulative distributions (see fig. S7). Error bars represent 95% bootstrap CIs.

The observed diversity in K1/2 values might thus reflect cell-to-cell differences in the value of n, m*, or both. To discriminate between these possibilities, we first considered two models that represent limiting cases (Fig. 4B and fig. S6). In model 1, the value of m* is fixed across cells, but the value of n varies across the population. In model 2, n is fixed and m* varies. Both models could fit the distribution of steady-state kinase activity (Fig. 4C) previously measured in isogenic populations (25), as well as the population-averaged dose-response data (Fig. 4D). However, the two models yield contrasting predictions for the underlying diversity in single-cell sensitivity. Whereas model 1 with variability only in the size of receptor coupling n demonstrated a tuning of K1/2 diversity upon adaptation to MeAsp in close agreement with the experimental data, model 2 with variability only in m* demonstrated little or no diversity tuning, with the width of the K1/2 distribution remaining approximately constant, with or without adaptation to MeAsp (Fig. 4E). A more general model in which both n and m* vary across cells also yielded consistent results: Fitting with this model yielded a broad distribution for n (CV(n) = 0.41) but a very narrow one for m* (CV(m*) = 0.02) (fig. S8). In a similar manner, the observed diversity tuning of response sensitivity to serine stimuli could also be explained by the variation in the number of coupled Tsr receptors while keeping m* fixed (fig. S5).

Thus, MWC modeling implicates as the predominant source of response diversity a single parameter, the degree of allosteric coupling n for the receptor cognate to the applied ligand stimulus. The model yields excellent fits to the changes in the shape of the K1/2 distribution p(K1/2) upon adaptation without assuming any changes in the underlying parameter distribution p(n). Consistently, further model-based analysis of the dose-response data (fig. S9 and Supplementary Text) did not detect significant changes in the distribution p(n) over the different backgrounds [L]0 across which diversity tuning (i.e., a change in the width of p(K1/2)) is observed. These modeling results thus suggest that while variation in n is the key ingredient for response diversity, the posttranslational mechanism that accounts for adaptive tuning of that diversity does not require a change in the degree of variation in n across cells.

To pinpoint the mechanism responsible for diversity tuning with the MWC model, we focused on the simplest variant (model 1) that reproduced the observed diversity tuning assuming cell-to-cell variation in only a single parameter, n. We first investigated how diversity in K1/2 (as quantified by its coefficient of variation, CV(K1/2)) depends on the adapted state background [L]0 in this model while holding fixed the distribution p(n). CV(K1/2) demonstrated two plateaus: At low [L]0, K1/2 is highly variable with CV(K1/2) approaching 0.5, whereas at high [L]0, diversity is strongly suppressed with CV(K1/2) attenuated by nearly an order of magnitude (Fig. 5A, gray curve). Thus, diversity in response sensitivity demonstrates two regimes: high diversity at low [L]0 and low diversity at high [L]0.

(A) The adaptive MWC model predicts a switch from high to low sensory diversity as the background stimulus level [L]0 is increased from zero. The coefficient of variation of K1/2 (CV(K1/2)) at [L]0 = 0 M and [L]0 = {100,200} M MeAsp (black points) falls within the high- and low-diversity regimes, respectively, predicted by model 1 (gray curve). To test the predicted transition regime, we measured the K1/2 distribution at the crossover point [L]0*=KI(e(m0m*)1)2.1M (dotted line). The measured CV (magenta) for cells adapted to [L]0=2M([L]0*) is in excellent agreement with the model prediction (blue point). All CV values were computed from parameters of the log-normal distributions fitted to the CDF of K1/2 (fig. S12). Error bars were computed by propagating the SE of the parameters. (B) The model accurately predicts the full distribution of K1/2 diversity and the population-level response at [L]0*. Model prediction (blue) and experimental results (magenta) for the population dose-response curve (top), CDF (middle), and probability density function (PDF, bottom) of K1/2 at [L]0 = 2 M MeAsp. Model parameters were constrained only by the data at [L]0 = {0,100,200} M data (Fig. 4), with no additional fit parameters for the [L]0 = 2 M data. Model behavior at [L]0 = {0,100,200} M backgrounds is shown for reference (gray dashed curves). Error bars represent 95% bootstrap CIs.

A key quantity that determines how the diversity in n affects diversity in K1/2 is the susceptibility of K1/2 with respect to n, defined by the absolute partial derivative n log (K1/2). In broad terms, when this susceptibility is high, variation in n contributes strongly to diversity in K1/2; when it is low, the effects of variation in n can be suppressed. We found that the susceptibility n log (K1/2) computed using the MWC model (and evaluated at the population mean, n = n) also exhibits a decreasing profile as a function of [L]0 with two plateaus (fig. S10), closely mirroring the CV(K1/2) profile (Fig. 5A, gray curve).

The existence of two regimes with contrasting susceptibilities n log (K1/2) has been predicted theoretically for chemoreceptor MWC models [fig. S11; (37)]. In this class of models, the methylation-dependent free energy difference between the active and inactive states of ligand-unbound receptors follows a linear relationship fm = (m([L]0) m0), where corresponds to the free energy per methyl group, and m0 is an offset methylation level at which fm = 0. Because of nonlinearities arising in the allosteric mechanism, the dependence of K1/2 on n changes qualitatively as the methylation level crosses m0 [fig. S11; (37)]. When the methylation level is low (i.e., m([L]0) < m0), K1/2 becomes inversely proportional to n (specifically, K1/2 KI/n, where the dissociation constant of the inactive receptor KI sets the concentration scale), and therefore, the degree of receptor coupling n strongly affects sensitivity. In this regime, the susceptibility n log (K1/2) is thus high, and we can expect cell-to-cell variation in n to cause substantial K1/2 diversity across cells. Conversely, when the methylation level is high (i.e., m([L]0) > m0), K1/2 becomes independent of n (37). In this regime, the susceptibility n log (K1/2) is thus low, and we can expect K1/2 diversity to be suppressed. The crossover between the two regimes is set by the offset methylation level m0 at which the free-energy contribution from covalent modification feedback vanishes (i.e., fm = (m([L]0) m0) = 0). Thus, the drastic difference in diversity we found at zero and high (100 and 200 M) background concentrations (Fig. 5A, black points) could be explained by the switch from high to low susceptibility n log (K1/2) as the adapted-state covalent modification level m([L]0) increases beyond m0.

The success of the adaptive MWC model in explaining the observed response diversity motivated us to further test its predictive power: Given the model calibrated by data obtained so far in the high- and low-diversity regimes, how accurately could we predict K1/2 diversity at an as-yet unmeasured background concentration? Using experimentally determined values for the parameters KI, , m0 (14, 20), and m*, the crossover background concentration [L]0* at which the adapted state modification level reaches m0 (i.e., m([L]0*)=m0) is readily computed from the model (see the Supplementary Materials) as [L]0*=KI(e(m0m*)1)2.1 M MeAsp (Fig. 5A, vertical dashed line), at which the model predicts an intermediate level of K1/2 diversity (Fig. 5A, blue point). We thus opted to measure the distribution of K1/2 at a background of 2 M (Fig. 5 and fig. S12). The results are in excellent quantitative agreement with model predictions not only at the level of CV(K1/2) (Fig. 5A, magenta point) but also for the entire shape of the distribution (Fig. 5B, middle and bottom) and population-level response (Fig. 5B, top).

Thus, the adaptive MWC model of chemoreceptors provides not only a mechanistic explanation for but also predictive power over the observed diversity tuning in the bacterial chemotaxis system, in which posttranslational receptor modification mediates the transition between two regimes of sensory diversity: When the background stimulus level is low (regime I), receptor modification falls below m0 and diversity is augmented; when the background stimulus is high (regime II), modification exceeds m0 and response diversity is attenuated.

By combining a novel microfluidic device with a single-cell FRET assay, we characterized the diversity of chemoeffector responses and its dependence on background stimulus conditions within isogenic populations of E. coli. We found that the width of the sensitivity distribution is strongly modulated in an environment-dependent manner under experimental conditions (auxotrophic limitation) that do not permit gene expression changes. Mathematical modeling provided remarkably accurate predictions and a mechanistic explanation for this diversity tuning that requires only a change in the posttranslational modification of signaling proteins. Below, we discuss the molecular requirements and functional implications of this novel mechanism for diversity tuning, as well as the significance of its implementation without changes in gene expression.

It has long been known that the intracellular variable modulating bacterial chemotactic sensitivity upon sensory adaptation is the covalent modification level m of chemoreceptors (43, 44). Naively, therefore, one might expect the diversity in sensitivity we observed across cells to be the result of cell-to-cell differences in this key internal variable. Our MWC model analysis revealed, however, that the main contribution to response diversity comes not from m but instead from n, the degree of chemoreceptor coupling. While n is a coarse-grained parameter that can be affected by both the size and composition of receptor clusters, the likely dominant contribution to its variation is the expression-level ratio between the two major receptor species Tar and Tsr, which has been shown to vary strongly across cells (45). A recent study in adaptation-deficient cells found that the diversity in dose-response parameters (K1/2 and the Hill coefficient, H) across cells could be largely explained by variation in this ratio (25). Varying the Tar/Tsr ratio determines the direction of chemotactic cell migrations when subjected to two conflicting chemoeffector gradients (46)whereas cells with high Tar/Tsr ratios migrate preferentially toward MeAsp (the cognate ligand for Tar), cells with low Tar/Tsr ratios do so toward serine (the cognate ligand for Tsr). Thus, the diversity in response sensitivity we observed in our FRET experiments can be interpreted to reflect diversity in sensory preference, which could, in turn, significantly affect population-level chemotactic performance in environments that present multiple stimuli.

Optimal strategies for biological adaptation depend on accessible information about the environment (47, 48). When environmental cues provide sufficiently accurate information, tracking strategies that accordingly adjust phenotypes can provide an advantage. When environmental cues do not carry sufficient information, bet-hedging strategies can provide readiness of different individuals to different environments.

For sensory adaptation in bacterial chemotaxis, the zero-background condition is singular in that there is no information about the nature of future environmental signals. E. coli cells express five types of chemoreceptors (Tar, Tsr, Tap, Trg, and Aer) that sense a variety of stimuli (10). Given that the relative expression levels of these receptors are highly variable across cells (45) and that different receptor species are mixed within clusters (49), the combinations of the effective degree of coupling for each receptor type realized in a cell population are numerous.

The switch-like transition in K1/2 diversity we observed (Fig. 5) enables cells to diversify their response sensitivities (and hence sensory preference) for different ligands when all ligand concentrations are near zero and uncertainty is at a maximum (Fig. 6A). This could be beneficial in improving the readiness of the isogenic population for many future signalsa sensory bet-hedging strategy. By contrast, once a relevant signal is detected, such as a gradient of aspartate, cell-to-cell variability in sensitivity can lead to detrimental desensitization (when sensitivity is too low) or sensory saturation (when sensitivity is too high) that precludes effective tracking of the signal as cells climb the gradient by chemotaxis. Our experiments revealed that the width of the distribution of sensitivities is markedly reduced upon adaptation to higher ligand concentrations, therefore focusing the population on tracking that signal. In summary, this novel mechanism of sensory diversity tuning could enable an isogenic population to be ready for any signal when the environment is uncertain but switch to tracking a specific signal once it is detected.

(A) Diversity tuning in chemotactic response sensitivity. In environments with low background signals below the crossover level ([L](x)<[L]0*), uncertainty about future signals is high, and the population diversifies its sensory preference. In environments with high background signals above the crossover level ([L](x)>[L]0*), the population can attenuate its sensory diversity and switch to tracking the perceived signal. (B) Phenotypic diversity can be tuned by environmental modulation of either gene expression or posttranslational processes. Top: Gene expressiondependent diversity tuning involves modulation of stochastic gene expression in response to environment changes (79), leading to different distributions of expressed protein counts across cells in different environments. This mechanism can tune phenotypic diversity without environmental modulation of posttranslational expression-phenotype mappings (represented here by the box labeled by f). Bottom: By contrast, the posttranslational diversity tuning mechanism we found in this study involves environmental modulation of the expression-phenotype mapping (f, implemented in bacterial chemotaxis by covalent modification of allosteric chemoreceptors). This mechanism requires no environmental modulation of gene expression and hence can achieve rapid tuning of phenotypic diversity.

Another challenge unique to the zero-background signal condition is that there is no information about the magnitude of the future signal. In dealing with the uncertainty in the signal strength, two key performance measures of a cell population as a sensory system are the width of the range of input signals over which it can respond (response range; fig. S13A) and the degree to which the input signal is amplified at the output level (gain; fig. S13A). For a homogeneous cell population with a sigmoidal stimulus-response curve, it is known that there is an inherent trade-off between these two performance measures (50, 51). A large response range requires a shallow response curve, but this inevitably reduces the response gain, and vice versa (fig. S13B). To understand whether and how the diversified sensitivity contributes to the performance of a cell population, we computed the performance measures of gain and response range in the zero-stimulus background condition using the MWC model and compared a cell population with diversity in the number of coupled receptors n to a hypothetical homogenous population (fig. S13B). As expected from the diversity in the sensitivity due to the variation in n, the diverse population exhibits a broader response range than the homogeneous population (fig. S13B). On the other hand, each individual cell in the diverse population maintains a high response gain (fig. S13B), reflecting the insensitivity of the gain to the variation in n in the low-background signal regime of the coupled two-state receptors (37). Thus, a population with diverse sensitivity can outperform homogeneous populations in dealing with the unpredictability associated with the zero background.

As noted above, the high- and low-diversity regimes we found here were identified in an earlier theoretical study as regimes I and II, respectively, of cooperative chemosensing (37). In that study, it was found that cooperativity (i.e., n > 1) extends the dynamic range of sensing to lower concentrations due to the 1/n scaling of K1/2 in regime I, whereas it increases signal gain by increasing the steepness of response (i.e., the Hill coefficient, H > 1) in regime II. Subsequent studies found that when E. coli cells are adapted to higher concentrations in regime II ([L]0 KI), responses to step changes (39) and time-varying signals (18, 19) depend only on relative changes of chemoeffector concentrations (14). This property of FCD provides a robust sensory strategy in many natural contexts where absolute signal intensities tend to carry less information than relative contrast (19). By contrast, in regime I of cooperative sensing ([L]0<[L]0*), the sensory response becomes proportional to the absolute change in chemoeffector input. Although this connection between the cooperative sensing regimes and FCD is intriguing, we note that the diversity tuning we found here is not causally related to FCD. One can construct a network model that demonstrates the linear-response/FCD transition but does not demonstrate diversity tuning (see the Supplementary Materials and fig. S14). Evidently, cooperativity in E. coli chemoreceptors provides multiple benefits in sensory performance: increased dynamic range/signal gain, FCD, and diversity tuning of response sensitivity. The molecular parameters that define cooperativity and the resulting signaling regimes are thus likely under pleiotropic selection (52) and would provide fertile ground for future studies of trade-offs and optimality (53) in the design of allosteric signaling systems.

Recent pioneering studies have provided a handful of examples of how bacteria can modulate phenotypic diversity in an environment-dependent manner, by changing the distribution of protein abundance across cells [Fig. 6B, top; (79)]. By contrast, the diversity-tuning mechanism we found here is implemented by posttranslational processes (Fig. 6B, bottom). The mechanism hinges on a nonlinear relationship (represented by the box with label f in Fig. 6B, bottom) between the phenotype of interest (here, the response sensitivity or its inverse, K1/2), a gene expressiondependent parameter (here, the degree of receptor coupling, n), and a posttranslational variable that varies in response to the environment (here, the covalent modification state of chemoreceptors, m).

An important difference between gene expressiondependent and posttranslational mechanisms of diversity tuning lies in the achievable speed for environment-dependent modulation of diversity. Whereas the former is limited by the time scale of gene expression (typically measured in minutes), the latter can be implemented by much faster biochemical processes (the fastest covalent modifications occur on subsecond time scales). Another significant difference is in biochemical costs and requirements: Gene expressiondependent diversity tuning requires synthesis of new proteins and hence may be rendered useless under nutrient-limited conditions, whereas the posttranslational mechanism studied here could be operational in any environment that supports the required type of covalent modification (here, methylation). Thus, posttranslational diversity tuning could be advantageous when cell populations need to adapt to fast-switching environments such as the gut (54, 55) and/or under poor nutrient conditions such as marine environments (56). Given the ubiquity of nonlinear functions throughout cellular biochemistry, we expect that posttranslational diversity tuning could play a role in the survival of a broad range of cell types in a variety of biological contexts.

The strain used is a derivative of E. coli K-12 strain RP437 (HCB33). The FRET acceptor-donor pair (CheY-mRFP and CheZ-mYFP) is expressed in tandem from plasmid pSJAB106 (25) under an isopropyl--d-thiogalactopyranoside (IPTG)inducible promoter with induction level of 50 M IPTG. The glass-adhesive mutant of FliC (FliC*) was expressed from a sodium salicylate (NaSal)inducible pZR1 plasmid (25) with induction level of 3 M NaSal. We transformed the plasmids in VS115, a cheY cheZ fliC mutant of RP437 [a gift of V. Sourjik; (25)], referred to as wild-type strain in the main text.

Microfluidic devices were constructed from PDMS on a 24 mm 60 mm cover glass (#1.5) following standard soft lithography protocols (57). Briefly, the master molds for the device were created with a positive photoresist (AZ 9260, MicroChemicals) on a silicon wafer using a standard photolithography technique (57). Approximately 20-m-high master molds were created. To fabricate the device, the master molds were coated with a 5-mm-thick layer of degassed 10:1 PDMS-to-curing agent ratio (Sylgard 184, Dow Corning). The PDMS layer was cured at 80C for 1 hour and then cut and separated from the wafer, and holes were punched for the inlets and outlet. The PDMS device was then bonded to a cover glass. The PDMS was cleaned with transparent adhesive tape (Magic Tape, Scotch) followed by rinsing with (in order) isopropanol, methanol, and Millipore-filtered water. The glass was rinsed with acetone, isopropanol, methanol, and Millipore-filtered water. The PDMS device was tape-cleaned an additional time before the surfaces of the device and coverslip were treated with a plasma generated by a corona treater. Then, the PDMS device was laminated to the coverslip and then baked at 80C overnight.

Sample preparation in the microfluidic device was conducted as follows: Of the five inlets of the device (fig. S1A), four inlets are connected to reservoirs (liquid chromatography columns, C3669; Sigma-Aldrich) filled with motility media containing various concentrations of MeAsp through polyethylene tubing (Fine Bore Polythene Tubing, 0.58 mm inside diameter, 0.96 mm outer diameter, Smiths Medical). Another inlet (located at the extremity) is connected to a reservoir filled with motility media containing fluorescein, which enables us to observe the flow of the solution and allows us to calibrate the pressure applied to the reservoirs before each experiment. The tubing was connected to the PDMS device through stainless steel pins that were directly plugged into the inlets or outlet of the device. Cells washed and suspended in motility media were loaded in the device from the outlet of the device and attached to the glass surface in the microfluidic device by reducing the flow speed inside the chamber. The pressure inside the reservoirs connected to the inlets was controlled by computer-controlled solenoid valves (MH1, Festo) that promptly switches between atmospheric pressure and higher pressure introduced from a source of pressurized air. The pressure applied to the reservoirs was adjusted before each experiment by observing the flow of the fluorescent solution under the microscope so that all stimulus solutions are delivered to imaging areas. The FRET measurements were conducted at three different positions in a microfluidic device, and an identical stimulus protocol was repeated at every position.

Single-cell FRET microscopy and cell culture were carried out essentially as described previously (25). In brief, cells from a saturated overnight culture were grown to OD 0.45 to 0.47 in 10 ml of tryptone broth (1% bacto-tryptone and 0.5% NaCl) in the presence of ampicillin (100 g/ml), chloramphenicol (34 g/ml), 50 M IPTG, and 3 M NaSal. Cells were collected by centrifugation (5 min at 5000 rpm) and washed twice with motility media [10 mM KPO4, 0.1 mM EDTA, 1 M methionine, and 10 mM lactic acid (pH 7)] and then resuspended in 2 ml of motility media.

FRET imaging in the microfluidic device was performed using an inverted microscope (Eclipse Ti-E, Nikon) equipped with an oil immersion objective lens (CFI Apo TIRF 60 Oil, Nikon). Yellow fluorescent protein (YFP) was illuminated with a light-emitting diode illumination system (pE-4000, CoolLED, for experiments with MeAsp stimuli, and SOLA SE, Lumencor, for experiments with serine stimuli) through an excitation bandpass filter (FF01-500/24-25, Semrock) and a dichroic mirror (F01-542/27-25F, Semrock), and the fluorescence emission was led into an emission image splitter (OptoSplit II, Cairn) and further split into donor and acceptor channels with a second dichroic mirror (FF580-FDi01-25x36, Semrock) and collected through emission bandpass filters (FF520-Di02-25x36 and FF593-Di03-25x36, Semrock) with a sCMOS (scientific CMOS) camera (ORCA-Flash4.0 V2, Hamamatsu). Red fluorescent protein (RFP) was illuminated in the same way as YFP except that an excitation bandpass filter (FF01-562/40-25 for experiments with MeAsp stimuli and FF01-575/05-25 for experiments with serine; both from Semrock) and a dichroic mirror (FF593-Di03-25x36, Semrock) were used. Additional excitation filter (59026x, Chroma) was used for experiments with serine stimuli. Before each time-lapse measurement, an acceptor image (RFP excitation and RFP emission) and a donor image (YFP excitation and YFP emission) were taken to estimate the RFP expression level and cell volume of each cell used for data analysis. In time-lapse imaging, images were acquired every 0.3 to 0.5 s.

The FRET level of each cell was calculated essentially in the same way as described previously (21, 25, 32). After flat-field correction of the fluorescent images, fluorescent signals, i.e., donor signal (obtained from donor channel: YFP excitation and YFP emission) and FRET-acceptor signal (obtained from FRET-acceptor channel: YFP excitation and RFP emission), were extracted from the images for each individual cell using an image segmentation technique. The extracted raw fluorescent time series were corrected for bleaching by fitting both donor and FRET-acceptor signals with a biexponential function and dividing out the decay to yield donor signal D(t) and FRET-acceptor signal A(t).

We define the FRET index as the decrease in the donor signal D(t), D (0), due to FRET between the donor (mYFP) and acceptor (mRFP1) molecule, normalized by the intensity of donor illumination reaching a cell through the donor excitation filter, D, and cell volume, VcellFRET(t)D/(DVcell)where D was extracted from the flat-field image, and Vcell was estimated from the no-binning YFP image. The FRET index was chosen because D/(DVcell) is proportional to the concentration of active CheA. To show this, we consider the following. First, D can be decomposed asD=DDEFRETQDLDSDtDDVcell[DA]where D, EFRET, QD, LD, SD, tDD, and [DA] are respectively the absorption coefficient of donor, the FRET efficiency of the complex, the quantum yield of donor, the throughput of the donor emission light-path, the quantum sensitivity of the camera for donor emission, the exposure time for the donor image, and the concentration of the donor-acceptor complex. Because D, EFRET, QD, LD, SD, and tDD are all constants once the experimental system is fixed, by introducing C = DEFRETQDLDSDtDD, we write D asD=CDVcell[DA]

So, the FRET index FRET(t) is proportional to [DA] or the concentration of CheYp-CheZ complex [CheYp CheZ]. The concentration of the complex reaches a quasisteady state on the time scale larger than the time scale of hydrolysis of phosphorylated CheY, CheYp, catalyzed by CheZ [~0.5 s; (22)] due to the balance between phosphorylation and dephosphorylation of CheY. Thus, the following holds[DA]=[CheYpCheZ]=akAkZ[CheA]=akAkZ[CheA]Twhere kA and kZ are respectively the rate constants for autophosphorylation of CheA and that for hydrolysis of CheYp by CheZ, a (0 < a < 1) is the fraction of active CheA, and [CheA]T is the total concentration of CheA (25). Given the conservation equation [CheA]T = [CheA] + [CheAp], the last step of the above equations holds when [CheAp] [CheA]T. This is achieved when sufficient amount of CheY-RFP and CheZ-YFP is present in the cell as verified previously (25), and therefore, we exclude cells from analysis whose concentrations of CheY-mRFP1 and CheZ-mYFP are low.

Together, the FRET index isFRET(t)=DDVcell=C[DA]=CkAkAa[CheA]T=Ca[CheA]Twhere C = CkA/kZ, which is invariant between cells. To increase the signal-to-noise ratio, D can be computed, rather than directly extracting from D(t), asD(t)=D0r(t)+r0+r(t)where r(t) A(t)/D(t) = r0 + r(t); r0 and D0 are the ratio r and donor signal D, respectively, in the absence of FRET, which is obtained by applying saturating stimulus to cells (21); and = A/D is the absolute value of the ratio of changes in the fluorescent signals due to FRET, which is a constant dependent on a measurement system (21, 25, 32). Fss was defined as the average FRET index excluding time points during and right after stimuli (15 s for a saturating stimuli and 6 s for subsaturating step stimuli). Fi was defined as the median FRET index during a step stimulus (10 time points). Response to each step stimulus Ri was defined as Ri = Fi/Fss.

A measured FRET time series FRET(t) can be conceptually decomposed into the true signal FRETtrue(t), which is proportional to the concentration of active CheA, and the measurement noise arising from the finite number of photons (t)FRET(t)=FRETtrue(t)+(t)

Because the true signal is also fluctuating, it is not trivial to estimate the magnitude of the measurement noise in general. However, we can exploit the fact that, when a saturating stimulus is presented, the true signal, and therefore also its variance, goes to zero (21) and henceFRET(tsat)=(t)

Thus, the variance of the FRET time series during a saturating stimulus can be equated with the measurement noiseVar(FRET(tsat))=Var()

When evaluating a FRET level upon a stimulus, we used the median value of n (=10) consecutive measurement points to mitigate the contribution of measurement noise. Because the measurement noise is delta correlated, the contribution of measurement noise is Var(FRET(tsat))/n. We estimated this quantity by computing the SE of the mean from n consecutive data points during saturating stimuli from each cell and then computed the ensemble average of the value (fig. S2).

Using the identity p(K1/2 < [L]) = p(R < 0.5) (Fig. 2), the response distributions were converted to the CDF of the response constant K1/2 as schematically shown in Fig. 2A. The error bar of the estimated p(K1/2 < [L]) was obtained by bootstrapping over single responses (95% CI). The data were fitted by the CDF of the log-normal distribution y(x)=0x1x(2)1/2exp((lnx)2/22)dx by the weighted least square fitting method. The weights were given by the inverse of the width of the 95% CI except the data points of [L] = 0 (no step stimulus) and [L] = [L]sat (saturating stimulus), which were weighted with an arbitrary high value. Extracted parameters and their SE were (, ) = (0.822 0.069,0.51 0.12) for [L]0 = 0 M, (, ) = (1.659 0.039,0.291 0.027) for [L]0 = 2 M, (, ) = (4.715 0.012,0.051 0.006) for [L]0 = 100 M, and (, ) = (5.442 0.014,0.052 0.010) for [L]0 = 200 M.

For MeAsp responses, we considered the following three different types of the MWC model, each of which has different variations in the parameter values of m* and n. Model 1: m* is fixed, but n varies. Model 2: m* varies, but n is fixed. Model 3: both m* and n vary. When the parameters are allowed to vary, we assumed the normal distribution for m*, f(m*m,m2), and the log-normal distribution for n, g(nn,n2). We determined the parameters (m*, n, n) for model 1 by the least square method, using the distribution of kinase activity a0, the dose-response curves, and the cumulative distribution of K1/2 (Fig. 4, C to E). The obtained values were (m*, n, n) = (0.445,2.018,0.387). For model 2, both the mean values of m* and n were fixed to the same values as the means of those of model 1, m* = 0.445 and n = 8.1. The SD of m*, m, was chosen to minimize the mean squared error in fitting to the distribution of kinase activity a0, which gave m = 0.02. For model 3, all the parameter values were determined in the same way as model 1. The obtained parameter values were (m, m, n, n) = (0.446,0.010,2.035,0.385), and the correlation coefficient between m* and log(n) was 0.144. For serine responses, we considered only variation in n (model 1). The best-fit parameter values were (m*, n, n) = (0.4838,2.322,0.4174). In fig. S9 (A to D), model 1 was fitted to the data, allowing the log-normal distribution of n to depend on different background conditions, i.e., the parameters m*, n,0, n,0, n,100, n,100, n,200, and n,200 were estimated simultaneously, where the numbers in the subscript indicate the corresponding background MeAsp concentrations. The estimated parameters were m* = 0.455 (0.447 to 0.464), n,0 = 2.030 (1.950 to 2.148), n,0 = 0.409 (0.254 to 0.557), n,100 = 2.206 (2.048 to 2.323), n,100 = 0.426 (0.264 to 0.670), n,200 = 2.057 (1.896 to 2.171), and n,200 = 0.603 (0.449 to 0.872), where the maximum likelihood values and 95% CIs (shown in the parentheses) were obtained from the likelihood function estimated by the Metropolis-Hastings sampling method. The log likelihood function was defined as logL=2Nai=1Na(xii())22i21Ndj=1Nd(xjj())22j21NKk=1NK(xkk())22k2+C, where Na, Nd, and NK are the numbers of data points of the kinase activity distribution (Fig. 4C), the dose-response curves (Fig. 4D), and the CDF of K1/2 (Fig. 3B), respectively; x and are the data point and its uncertainty (SD estimated as 68% CI); () is model prediction; and C is the normalization constant of the likelihood function (which need not be specified for Metropolis-Hastings sampling). The weights in front of the summations were chosen such that it computes the average value of the residuals in each experiment, which gives more equal weight across experiments that might have different statistical power, and that the two datasets (i.e., one that gives the kinase activity distribution and one that gives both the dose-response curves and the CDF of K1/2) have an equal weight.

Acknowledgments: We thank S. Parkinson and V. Sourjik for strains; N. Frankel, A. Waite, and Y. Dufour for help with the microfluidics; S. Boskamp and Z. Rychanavska for cell culture and technical assistance; M. Kamp for microscopy assistance; E. Clay, B. Ait Said, and M. Konijnenburg for software and electronic support; F. Avgidis and S. Grannetia for help with experiments; and H. Mattingly and J. van Zon for discussions and critical reading of the manuscript. Funding: This study was supported by the Allen Distinguished Investigator Program (grant 11562) through the Paul G. Allen Frontiers Group, NIH award R01GM106189, NWO VIDI award 680-47-515, and NWO/FOM Projectruimte grant 11PR2958. Author contributions: K.K., T.E., and T.S.S. designed the research. T.E. and T.S.S. supervised the project and secured funding. K.K., J.M.K., T.E., and T.S.S. conceived the method. K.K. performed the experiments. K.K., T.E., and T.S.S. performed the data analysis and mathematical modeling. K.K. and J.L. performed theoretical analyses in the Supplementary Materials. K.K., J.M.K., T.E., and T.S.S. wrote the manuscript with input from J.L. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Continue reading here:
Adaptive tuning of cell sensory diversity without changes in gene expression - Science Advances

Frederick Health Hospital Physician Named One Of 10 Top Doctors In The Area – WFMD

November 16, 2020 - 2:05 pm

Its the third time for Dr. Meredith Wenick.

Frederick, Md (KM)) Washingtonian Magazines annual list of top doctors in the region includes a Frederick Health Hospital physician. Doctor Meredith Wernick was picked for the third time by the magazine as one of its top doctors in Maryland, Virginia and Washington DC. She was received this recognition in 2018 and 2019.

Being recognized by my colleagues in this way is truly an honor, Dr. Wernick says in a statement. Im very proud of the care we provide at Frederick Health. What I do is only possible thanks to our dedicated doctors, nurses and staff, al of whom have worked tirelessly to ensure uninterrupted treatment for our patients under extraordinary conditions since March.

Dr. Wernick is board-certified radiation oncologist who works with the Hospitals Radiation Oncology team.

She received her bachelors degrees in chemistry and molecular and cell biology at the University of California at Berkeley in 1996, and spent four yours as a researcher at the UCSF Center with a focus on the genetics of breast cancer, according to a news release from Frederick Health Hospital.

Dr. Wernick completed her medical training at Georgetown University, where she also completed an internship in internal medicine.

She currently sees patients at the James M. Stockman Cancer Institute in Frederick.

Dr. Wernick live in Potomac with husband and two sons.

By Kevin McManus

Go here to read the rest:
Frederick Health Hospital Physician Named One Of 10 Top Doctors In The Area - WFMD

Insights & Outcomes: Cellular bet hedgers and a message from a magnetar – Yale News

This month, Insights & Outcomes is mindful of the mental health implications of COVID-19, the moments when cells act like portfolio managers, and a missive from a Milky Way magnetar.

As always, you can find more science and medicine research news on YaleNews Science & Technology and Health & Medicinepages.

Magnetars, a type of neutron star believed to have an extremely powerful magnetic field, could be the source of some fast radio bursts (FRBs), according to a new study in the journal Nature. FRBs are extremely bright, fast radio emissions that can release more energy in a fraction of a second than the Sun generates over many years. Astronomers discovered the existence of FRBs a decade ago and continue to debate the cause of the signals.

This is the first evidence of an astrophysical source for one FRB, tying it to a galactic neutron star with a large magnetic field and providing evidence that at least some FRBs are consistent with extragalactic magnetars, based on the brightness of this event, said co-author Laura Newburgh, an assistant professor of physics at Yale. Newburgh developed new analysis and measurement information that helped establish the brightness of an FRB emanating from a nearby magnetar located in the Milky Way. The Canadian Hydrogen Intensity Mapping Experiment, a collaboration of 50 scientists, produced the research.

Age, sex, and underlying medical issues have been recognized as major risk factors for an adverse outcome from COVID-19 infection. Now Yale psychiatrists say doctors should also consider another factor that increases risk of death in the pandemic a patients mental health. A new study shows that patients with psychiatric disorders admitted to Yale New Haven Hospital for treatment of COVID-19 were significantly more likely to die than those without a diagnosed mental health disorder. The higher mortality rate held even after controlling for other risk factors such age, sex of the patient, and pre-existing health conditions. The authors theorized that psychiatric disorders such as depression may have a harmful effect on patients immune system response to infection. We need to consider the health of the mind as well as the body when considering treatment options for people diagnosed with COVID-19, said John Krystal, chair of the Department of Psychiatry and senior author of the study. Luming Li, assistant professor of psychiatry, was lead author of the study published in thejournal JAMA Network Open.

In times of stability, cell populations act like investors with large portfolios. They hedge their bets by diversifying receptors on the surfaces of individual cells, preparing the population for sudden swings in the environment. But how can these populations respond quickly to unanticipated changes when the process that dictates composition of those receptors the regulating activity of genes is typically so time consuming?

A new study of E. coli bacteria by Yale scientists shows that when receiving new environmental signals, the diversity of cellular portfolios is reduced 10-fold, allowing the cell population to adjust to changing circumstances.

Essentially, cells instantly stopped hedging their bets and adjusted their sensitivity to focus on following the present signal, effectively consolidating assets into a winning portfolio. The mechanism we found enables a population to very rapidly switch from a bet-hedging mode to an exploitation mode, said Yales Thierry Emonet,professor of molecular, cellular, and developmental biology and of physicsand co-senior author of the study. Before this study, all mechanisms reported to do so also involved gene expression, which is orders of magnitude slower.Keita Kamino is first author of the study, published in the journal Science Advances. The research was conducted in the labs of Emonet and co-senior author Thomas S. Shimizu, group leader at the AMOLF Institute.

Sidi Chen,assistant professor in the Department of Genetics and the Systems Biology Institute and member of the Yale Cancer Center, received a $50,000 research grant from the Alliance for Cancer Gene Therapy (ACGT) to advance a versatile, scalable technology for targeting difficult-to-treat cancers. The technology Chen developed is called MAEGI Multiplexed Activation of Endogenous Genes as an Immunotherapy which leveragesthe natural power of the immune system to fight tumors.

The ACGT Scientific Advisory Council finds Dr. Chens MAEGI technology to be unique and exciting because it simultaneously targets multiple differences and activates multiple immune system responses, said Kevin Honeycutt, CEO and president of ACGT. It has proven to be very effective in animal models. We believe our support will enable its advancement into the clinic where it would have major, life-saving impact on pancreatic and other difficult-to-treat cancers, such as melanoma, glioblastoma and triple negative breast cancer.

Continued here:
Insights & Outcomes: Cellular bet hedgers and a message from a magnetar - Yale News

Can We Recreate Every Human Cell Type In The Body? This UK Startup Thinks So. – Forbes

Bit Bio, a UK synthetic biology startup backed by Silicon Valley investors, has partnered with the ... [+] London Institute for Mathematical Sciences, marking a milestone in the fusion of biology and mathematics for coding human cells.

Theres a fundamental difference between Bit Bio and most other biotechnology startups. If you just need something to work once, you can find what you need with massive amounts of screening and testing think drug development, or finding a single bacterial cell with the desired qualities.

But, when we make the leap and turn biology into an engineering discipline we can predict, reproduce, and scale, things fall apart. Our understanding of life is too weak.

Thats the fundamental challenge Bit Bio, a UK-based startup, is taking on through a commercial partnership with a non-profit research institution, the London Institute of Mathematical Sciences (LIMS).

Together, they will take on a shared moonshot goal: recreating every human cell type in the body. Not only would this be a monumental scientific milestone, but access to human cells would also accelerate the development of cell therapies, which have always been limited to testing in mice.

Cellular reprogramming is as much of a mathematical problem as it is a biological one. What we've learned about cell types is that the boundaries between cell states and sub cell states sort of blur. If you stop trying to classify them in the traditional way, and just try to map the transcriptional state that is necessary to achieve such a state - then you suddenly have a completely different view on identity, explains Dr. Mark Kotter, the founder and CEO of Bit Bio.

Mark Kotter is a stem cell biologist and neurosurgeon at the University of Cambridge, and ... [+] Founder/CEO of Bit Bio.

Bit Bios cell reprogramming platform allows them to turn on gene expression at will, and flipping the right switches could transition one cell type to another. Thats why their computational team is using neural networks to map recorded gene transcription to cell states. However, it hasnt been the one-size-fits-all toolkit that it often seems to be.

Neural networks is a common buzzword tossed around the tech space. By imitating the circuitry in our brains, neural nets have learned to do tasks ranging from voice recognition and weather forecasting to identifying dementia from EEG recordings.

However, a problem that Kotter soon identified was that the moment you go into complex [biological] data, there's some off the shelf tools that everyone uses, but there isn't really that much math that's, you know, usable. It's not that that kind of maths doesn't exist or people haven't thought about it, it's just that it hasn't crossed the boundary.

How do you discover new biology in massive amounts of data? First, you need new math, and this collision of fields has already proved fruitful for both collaborators.

The interaction with people that come from a different planet, so to speak, is extremely useful, Kotter reflects. The main reason why I'm very excited about working with LIMS is that they are really some of the smartest people in this particular field.

Kotter met Thomas Fink, the founder of LIMS during his PhD in Cambridge, but never imagined they would one day be actively collaborators. Coincidentally, LIMS had a cell identity project on the back burner since 2012 the same year that Kotter began working on the problem.

This convergence embodies the merging of two fields that were not quite as far apart as they seemed. And in this interdisciplinary world, you see the human cell after us at the moment taking shape.

Im the founder of SynBioBeta, and some of the companies that I write about are sponsors of the SynBioBeta conference andweekly digest. Thank you toDesiree Hofor additional research and reporting in this article.

Read more here:
Can We Recreate Every Human Cell Type In The Body? This UK Startup Thinks So. - Forbes

McGill researchers awarded $1.5 million in NRC collaborative funding – McGill – McGill Reporter

On November 2, the National Research Council of Canada (NRC) announced the results of its collaborative funding program, with a total of over $44 million awarded to institutions across the country. McGill researchers were among the cohort with more than $1.5 million in project funds awarded. In all, 19 McGill projects were supported through these initiatives. The NRC collaborative funding program is organized into three separate themes:

The support of the NRC through this collaborative funding program partners the creativity and talent of our researchers with those at the NRC, said Martha Crago, Vice-Principal, Research and Innovation. Each of these projects has the potential to make a real impact on peoples lives.

One such example is the work of Bioengineering Professor Amine Kamen, who received support for two projects. The first leverages artificial intelligence (AI) to improve the production of biological agents such as vaccines through the pairing of virtual and physical bioreactors. The second examines at the genomic level the production of Adeno-Associated Virus (AAV) vectors. This could lead to dramatically reduced costs for the targeted delivery of gene therapy treatments.

Funding from the NRC is helping us develop these platform technologies, explained Kamen. They will help ensure our preparedness in the situation of emerging or re-emerging infectious diseases.

Another researcher to have two projects funded was Professor Odile Liboiron-Ladouceur. She has been working on methods to incorporate AI into the design of photonic components, which not only accelerates the design cycles but also pushes the performance of photonic integrated circuits a step further. These circuits have multiple applications, including fiber optic networks, satellite communications, medical diagnostics, and other areas.

Funding from NRC enables a fruitful collaboration with NRC world-class scientists who take part in the training of graduate students as next-generation leaders, said Liboiron-Ladouceur, citing another major benefit of the NRC program.

Professor Amine A. Kamen, Bioengineering, for Digital-twin of bioreactor for accelerated design and optimal operations in production of complex biologics and, Genome-wide CRISPR screen to identify genes that increase the yield and functionality of AAV vectors

Professor Odile Liboiron-Ladouceur, Electrical & Computer Engineering, for AI-assisted miniaturization of integrated photonic components and, Silicon Photonics multiplexer design with machine learning methods

Professor Yelena Simine, Science, for AI-Enabled Design of Aptamers

Professor Lawrence R. Chen, Electrical & Computer Engineering, for Terabit optical networks based on quantum dot lasers and photonic integration

Professor Sylvain Coulombe, Chemical Engineering, for Functionalized BNNTs for Energy Applications

Professor Sasha Omanovic, Chemical Engineering for Development of new composite/ functionalized cathodes for bio-electrochemical conversion of CO2 and CH4

Professor Parisa Ariya, Atmospheric & Oceanic Sciences, for Microcosm studies for improved detection, physicochemical process characterization and modelling of the transport, degradation and fate of microplastics in Canadian waters (COVID-19)

Professor Michael Strauss, Anatomy & Cell Biology, for Tracking the mechanism of antibody trafficking across the blood brain barrier with advanced 3D-structure

Professor Sylvain Coulombe, Chemical Engineering, for developing a scalable solvent-free process for functionalization of Boron Nitride Nanotubes

Professor Audrey Helene Moores-Franois, Chemistry, for functionalized chitosan nanocrystals as catalysts for organic transformation reactions

Professor Mark Driscoll, Mechanical Engineering, for full body medical image segmentation for simulation-ready finite element models

Professor Abdolhamid Shafaroud Akbarzadeh, Bioresource Engineering, for bio-inspired Architected Ceramics for High Temperature Applications

Professor Victoria Kaspi, Physics, for a time-domain digital signal processing backend for fast radio burst follow up

Professor Maryam Tabrizian, Biomedical Engineering, for one step multiplex aptamer selection and validation using magnetic nanoparticle aptamer library (aptaMAG) coupled to microfluidic surface plasmon resonance imaging biosensor

Professor Lyle Whyte, Natural Resources Sciences, for an improved bio-inorganic system to couple solar energy to microbial carbon dioxide fixation

Professor Donald Smith, Plant Science, for Core microbes for field pea farming

Professor Jeffrey Bergthorson, Mechanical Engineering, for Optimized configuration of metal energy carrier for renewable energy sources

Read the NRC press release

Link:
McGill researchers awarded $1.5 million in NRC collaborative funding - McGill - McGill Reporter

Bruker Corporation to Participate in the Jefferies Virtual London Healthcare Conference – Business Wire

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the Jefferies Virtual London Healthcare Conference. Gerald Herman, Chief Financial Officer, will participate in an analyst moderated question and answer session on behalf of the company on Wednesday, November 18, 2020 at 2:05 PM Greenwich Mean Time (9:05 AM Eastern Standard Time).

A live audio webcast of the question and answer session will be available on the Investor Relations section of the Company's website at https://ir.bruker.com . A replay will be posted in the Events & Presentations section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the event.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Brukers high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: http://www.bruker.com.

Follow this link:
Bruker Corporation to Participate in the Jefferies Virtual London Healthcare Conference - Business Wire

UNC researchers believe a mutation may make COVID-19 more vulnerable to a vaccine – WRAL Tech Wire

CHAPEL HILL A new study published inScienceconfirms that SARS-CoV-2 has mutated in a way thats enabled it to spread quickly around the world, but the spike mutation may also make the virus more susceptible to a vaccine.

The new strain of coronavirus, called D614G, emerged in Europe and has become the most common in the world. Research at theUniversity of North Carolina at Chapel Hilland theUniversity of Wisconsin-Madisonshows the D614G strain replicates faster and is more transmissible than the virus, originating in China, that spread in the beginning of the pandemic.

There were bright spots in the study findings: While the D614G strain spreads faster, in animal studies it was not associated with more severe disease, and the strain is slightly more sensitive to neutralization by antibody drugs.

The study provides some of the first concrete findings about how SARS-CoV-2 is evolving.

The D614G virus outcompetes and outgrows the ancestral strain by about 10-fold and replicates extremely efficiently in primary nasal epithelial cells, which are a potentially important site for person-to-person transmission, saidRalph Baric, PhD, professor of epidemiology at the UNC-Chapel HillGillings School of Global Public Healthand professor of microbiology and immunology at theUNC School of Medicine.

PPD lands praise from partner Moderna which reports strong results for COVID-19 vaccine

Baric has studied coronaviruses for more than three decades and was integral in the development ofremdesivir, the first FDA-approved treatment for COVID-19.

Researchers believe the D614G strain of coronavirus dominates because it increases the spike proteins ability to open cells for the virus to enter. These crown-like spikes give the coronavirus its name.

The D614G mutation causes a flap on the tip of one spike to pop open, allowing the virus to infect cells more efficiently but also creating a pathway to the virus vulnerable core.

With one flap open, its easier for antibodies like the ones in the vaccines currently being tested to infiltrate and disable the virus.

For the recent study, Baric Lab researchers including first author Yixuan J. Hou, PhD worked in collaboration withYoshihiro Kawaoka, PhD, and Peter Halfmann, PhD, both virologists at the University of Wisconsin-Madison. UNC School of Medicine authors are Richard Boucher, MD, director of the UNC Marsico Lung Institute; Rhianna E. Lee, a graduate student in the UNC Department of Cell Biology and Physiology; Teresa M. Mascenik, a research specialist; and Scott Randell, PhD, associate professor of cell biology and physiology and Marsico member.

The original spike protein had a D at this position, and it was replaced by a G, Kawaoka said. Several papers had already described that this mutation makes the protein more functional and more efficient at getting into cells.

That earlier work, however, relied on a pseudotyped virus that included the receptor-binding protein but was not authentic. Using reverse genetics, Barics team replicated a matched pair of mutant SARS-CoV-2 viruses that encoded D or G at position 614 and compared basic property analysis using cell lines, primary human respiratory cells, and mouse and hamster cells.

Kawaoka and Halfmann contributed their unique coronavirus study model, which uses hamsters. The University of Wisconsin-Madison team including Shiho Chiba, who ran the hamster experiments performed replication and airborne transmission studies with both the original virus and the mutated version created by Baric and Hou.

They found that the mutated virus not only replicates about 10 times faster its also much more infectious.

Hamsters were inoculated with one virus or the other. The next day, eight uninfected hamsters were placed into cages next to infected hamsters. There was a divider between them so they could not touch, but air could pass between the cages.

Researchers began looking for replication of the virus in the uninfected animals on day two. Both viruses passed between animals via airborne transmission, but the timing was different.

With the mutant virus, the researchers saw transmission to six out of eight hamsters within two days, and to all the hamsters by day four. With the original virus, they saw no transmission on day two, though all of the exposed animals were infected by day four.

We saw that the mutant virus transmits better airborne than the [original] virus, which may explain why this virus dominated in humans, Kawaoka said.

The researchers also examined the pathology of the two coronavirus strains. Once hamsters were infected, they presented essentially the same viral load and symptoms. (The hamsters with the mutated strain lost slightly more weight while sick.) This suggests that while the mutant virus is much better at infecting hosts, it doesnt cause significantly worse illness.

Researchers caution that the pathology results may not hold true in human studies.

SARS-CoV-2 is an entirely new human pathogen and its evolution in human populations is hard to predict, Baric said. New variants are continually emerging, like the recently discovered mink SARS-CoV-2 cluster 5 variant in Denmark that also encodes D614G.

To maximally protect public health, we must continue to track and understand the consequences of these new mutations on disease severity, transmission, host range and vulnerability to vaccine-induced immunity.

(C) UNC

Go here to see the original:
UNC researchers believe a mutation may make COVID-19 more vulnerable to a vaccine - WRAL Tech Wire

I want to give my child the best: the race to grow human breast milk in a lab – The Guardian

Dr Leila Strickland became a mother when she was a few months away from completing her postdoctorate fellowship in cell biology at Stanford University. She spent the first three months of her sons life at home on maternity leave, relentlessly struggling to breastfeed. I was having a hard time producing enough milk. She never expected to find feeding her baby a greater challenge than advanced cytology.

My mom breastfed me and my sister until we were over two years old. All my life, Id fully embraced the proposition that breast milk is the best nutrition for a baby, and that this is what I would feed my baby. Lactation consultants, paediatricians and well-meaning friends told her to just keep trying. Because I was so unprepared for it, I found it really isolating. I felt like there was something wrong with me.

Eventually reluctantly Strickland decided to bottle-feed her baby with formula. It was convenient and practical, and made it possible for me to get more sleep, and for my husband to participate. In some ways I was able to be a better mom, and I was a lot happier, but I knew I was making a trade-off. I knew the product my child was getting was optimal for raising cows, that it didnt have the ideal nutrient composition. It was good enough but what mom is happy with good enough?

Eleven years later, Strickland has combined her experiences as both a stressed mother and a cell biologist in a way that could change how we feed our babies for ever: she has worked out how to make human breast milk without the human breast. Her startup, Biomilq, cultures breast cells in a lab farming them outside the body and collects the milk they secrete. The company calls it the mother of all patented technology and it has caught the eye of Bill Gates, who bought a $3.5m (2.7m) stake in Biomilq in June. Potentially, it could end the infant formula industry as we know it.

While the science shows breast is best helping cement the emotional connection between mother and child; providing optimal nutrition, antibodies and bacteria; reducing the risk of obesity and diabetes in adulthood breastfeeding can be a lottery. Many women find it straightforward and rewarding, but for others it is painful and demoralising. Sometimes babies have tongue-tie and wont latch on, or the mother has mastitis, or doesnt produce enough milk for the baby to put on the weight required to satisfy ever-watchful midwives and health visitors. Sometimes the baby is premature, or ill, and needs to be fed through a tube, or the mother is embarrassed about feeding in public, or needs to go back to work. Faced with these challenges, the most determined mothers might express milk with a pump; but pumping can be a time-consuming and often wretched experience.

The other alternative is formula. But, as Strickland says, it is a trade-off. Although their composition has improved, infant formulas are generally made from cows milk and therefore have sugars, proteins and fats best suited to calves. Human milk contains hormones, antibodies and friendly bacteria, as well as unique proteins and sugars. Formula also has a substantial carbon footprint; it is made from products that depend on dairy farming, or the cultivation of palm oil or soy. Theres also the shame many mothers feel after they turn to the bottle: women who use formula after struggling with breastfeeding have been shown to experience greater levels of guilt than mothers who chose not to breastfeed from the start.

Founded in January 2020, Biomilq boasts that it is women-owned, science-led and mother-centred. Strickland is juggling running the lab with homeschooling her two children through lockdown; in our video call from her house in North Carolina, she is casually dressed in a sweatshirt, and I can hear the sound of plates being knocked off tables in far-off rooms as we speak.

Growing food in a lab is called cellular agriculture and Strickland describes her work as if it were a kind of farming. We start with these amazing cells that line a womans mammary gland, she explains. Using the same techniques that weve used for decades to grow cells outside the body, were able to reproduce the behaviour these cells have evolved over millions of years, to produce components in quantities that match the babys needs.

Scientists have long been culturing cells for biomedical research, but it was in 2013, when Maastricht Universitys Mark Post served up a lab-grown hamburger to food critics on live TV, that the idea of making food from cells entered the public consciousness. Since then, dozens of startups worldwide have begun to make meat in the same way. No animal has to suffer and there are seemingly endless possibilities, from cruelty-free foie gras to kosher bacon.

Seeing Posts burger consumed live was a pivotal moment for Strickland. It was obvious to her that milk had to be next, though it poses a different technical challenge. Those guys have to harvest every single cell they grow and turn it into a product, she says. Her product is the secretion rather than the cell. Just as dairy farmers have different priorities to beef farmers, Stricklands product demands that she keeps her cells alive and producing for as long as possible, instead of selling them off as soon as they mature.

She started to do homespun experiments with her husband, who has a background in chemistry and engineering: he designed the scaffold on which the cells are grown and kept separate from their secretions. They rented a small lab space and spent about $5,000 (3,827) on used equipment from eBay, but the experiments were expensive. We were choosing between feeding cells and feeding our children. We had to choose our children, Strickland laughs. They used the cheapest source of mammary cells they could find: cow udders bought for $20 (15) a piece from the bewildered manager of the nearest slaughterhouse, taken to the lab and minced up.

Strickland monitored their growth in different conditions, and when she thought shed come up with the optimal technique, started experimenting with human breast cells, bought from commercial suppliers who normally provide them for breast cancer research. But she had no budget to test if her cells were actually producing human milk. For the most part, between 2013 and 2016, I just had a really expensive science hobby that most people in my life thought was extremely weird.

Burnt out, she gave up her lab in 2016. But no one else seemed to be pursuing her idea and it nagged away. In 2019, Strickland decided to make one more serious stab at this experiment. A mutual friend introduced her to Michelle Egger, who would eventually become Biomilqs CEO. Egger has a background in food science and had been working at the Bill and Melinda Gates Foundation. I know how to grow cells but I dont know anything about how to grow a company, so Michelle brought that crucial expertise, Strickland says.

Egger and Strickland got a commercial lab to run a proof-of-concept experiment, growing cells for a month and collecting samples every day. In February 2020, the results were in: the cells were producing the unique proteins and sugars found in human breast milk. The breakthrough led to the $3.5m investment from Gates, which will allow them to scale up the process, and which has changed Stricklands life. Im really doing my dream, she says. I get emotional in our meetings, because its really personal for me.

The breast milk Strickland produces in her lab is different from the milk that comes out of a human breast. It cant change in response to a babys needs, as milk from a breast can (for example, being diluted on hotter days when the baby needs more fluids); it contains no hormones or bacteria from the mothers biome. Most significantly, it has no antibodies, because these are imported into the milk from the mothers blood, which disembodied cells cant do. Thats a part of breast milk we wont be able to replicate, Strickland says, matter-of-factly.

She can afford to be relaxed about this, because Biomilqs market research suggests babies who drink their product will be getting breastfed anyway, and given Biomilq as a supplement. Those babies will be getting the antibodies from their own mother, then they will be getting a breast milk with a very similar composition when shes not able to breastfeed if she wants to go back to work, say, or sleep through the night. Their mission statement says their product is for women who need a little boost. Their target consumer is someone who is determined to breastfeed, but cant. Just like Strickland was.

But how liberating will lab-produced breast milk be? Its easy to imagine a scenario in which employers might be less willing to give women the space and time to breastfeed if a product like this exists. I do think we want to be careful and conscientious about things like that, Strickland says. We certainly wouldnt want to compromise any womans ability to breastfeed. She pauses. Any women who are at work and still trying to feed their babies breast milk are spending a good part of their day pumping. Thats what wed be targeting the pumping. Saving you from having to do that.

For Strickland, its about addressing the gulf between the expectations put on mothers and the reality. We want to celebrate breastfeeding, and encourage women to do it. Theres just not a great conversation going on about the challenges, she says. Most babies are not exclusively breastfed for six months [as recommended by the World Health Organization] and its not because women dont know or care about the benefits. Its because modern life really offers women no solution to achieve it.

***

The pressure not to accept the good enough provided by infant formula weighs heavily on mothers who want to breastfeed but are prevented from doing so by biology or circumstance. Its enough to have fuelled the growth of the underground online breast milk market. The invention of formula should have put an end to the practice of wet nursing; rather, the stigma attached to it has given rise to a new digital wet-nursing economy.

Services such as onlythebreast.com link up breast milk sellers with buyers, leaving it up to buyers to do their own screening. Searches can be narrowed down according to location, the age of the baby the milk has been produced for and whether the seller is following a specific diet: vegan, gluten-free or even paleo. The website advises that frozen expressed milk should be doubled bagged, wrapped in newspaper and put in a cooler with dry ice before being couriered to the recipient. It would set you back around 36 a day to feed the average month-old baby with milk bought here, priced at 1-1.50 an ounce, not including postage and packaging.

Of course, many women are happy to give their breast milk away for free. There are 15 hospital milk banks in the UK, providing screened, pasteurised donor milk, but it is destined for sick and premature babies in neonatal units. Mothers of healthy babies in search of breast milk often join one of Facebooks dozens of milk-sharing networks in hope of finding a nearby donor. The Human Milk 4 Human Babies UK Facebook group has more than 27,000 members. A new request for milk is posted every hour or so, often accompanied by photographs of tiny babies, wide-eyed with hunger.

The women posting on these forums have turned to social media out of desperation. One mother, who asked for donor milk to tide her four-week-old over while she works on topping up her supply, told me her failure to produce enough milk for him was an extremely painful experience. Everybody agrees that breast milk is a better option than formula.

Another mother began the search for breast milk a month before her second child was born. It was, she said, the best decision. She had tried everything to breastfeed her first baby, from renting a hospital-grade breast pump to taking drugs that might help boost lactation, but nothing worked. She now drives for at least an hour and a half every other week to collect frozen donor milk for her five-month-old son.

Human breast milk has nutritional ingredients formula simply doesnt, she said. I think of it as eating quality organic foods versus taking a synthetic supplement. It is the best thing I can give my child. When I sent a link to the Biomilq site, she replied, Wow. Finally. Shame [its] not available yet as I struggle to keep up with my sons demand. Will be forced to move on to formula.

Breast milk has become a symbol of optimal nutrition and optimal motherhood. But Joan Wolf, associate professor of womens and gender studies at Texas A&M University and author of Is Breast Best?, says women have been grossly misled about the extent of the advantages, because its impossible to disentangle the benefits of breast milk from the benefits of having a mother who wants to breastfeed.

You look at the sociology of breastfeeding, and the beliefs of women who breastfeed: they are determined to do everything they possibly can for their baby, she says. They are middle class; they feel theyve got to keep up with each other. Wolf argues that we increasingly feel we have a duty to reduce risk to ourselves or our families. Mothers must reduce any risk to an infant, no matter how small, and no matter the cost to the mother herself. Breast milk gets fetishised because of the risk element because its natural, and because it gives women a feeling of absolute power over their babies.

The availability of lab-grown milk wont assuage that desire to minimise all risks to your baby, Wolf says. One day we will have 15 different breast milks to pick from, each with different qualities. [Mothers] wont know which to pick. Theyll say, If I take this one the baby will get a gastrointestinal infection, or if I pick this one will they get cancer later. And this lab-grown breast milk could be very dangerous, because it could reinforce the idea that it really matters to breastfeed.

***

Stricklands work in the US may be groundbreaking, but she is not alone. She has an equally well-funded rival across the Pacific Ocean, backed by investors as diverse as British vegan private equity titan Jeremy Coller and Prince Khaled bin Alwaleed bin Talal Al Saud of Saudi Arabia.

We are the first biotech company in the world that is using cell-based methods to create milk, says Fengru Lin, founder and CEO of Singapores TurtleTree Labs, with the steely confidence of someone who is sure her company is not only first, but will be the best.

I speak to Lin and TurtleTrees chief strategist, Max Rye, in a video call to their respective homes in Lins native Singapore (Rye moved here from the US when they launched the company). Shes in an emerald blouse, her hair scraped back into a neat ponytail. He is every inch the relaxed American, leaning back on his sofa in a blue polo shirt. Before I even ask my first question, Rye tells me they want mothers to breastfeed. I always like to say, right at the beginning, we think its wonderful. We dont ever want that to stop. Theres nothing else like it, he says. Even though we can make human breast milk as a product, we are still far from the real thing.

Breast milk was an afterthought for TurtleTree Labs. The company began by culturing cows milk without the cow, and can now produce everything from sheeps and goats to camels milk, taking stem cells from freshly expressed milk and culturing them, instead of farming mammary cells as Biomilq does.

It started a few years ago when I was learning to make cheese as a hobby, Lin explains. It was difficult to find milk in Asia. There arent many cows in Singapore. She travelled around Indonesia and Thailand, and saw the problems of intensive dairy farming first-hand. Hormones and antibiotics are being pumped into the cows. As a result, the milk quality really suffers. They are impregnating the cow just to get her milk, again and again, every year. And the amount of methane cows create 37% of global emissions.

Lin was working as an account manager at Google at the time, and Rye, a tech executive, came to give a talk on new sustainable technologies. When he mentioned the startups growing meat from cells in a lab, Lins mind turned immediately to milk. Afterwards Fengru came up to me asking about milk, Rye says. And I thought, theres got to be someone working on this. There has to be. He holds his palms up in disbelief. But no, nobody was doing this.

They founded the company together in early 2019, and say it was feedback from dairy companies that prompted them to branch out into breast milk. The folks who provide milk in the stores are the same people who provide the raw ingredients for infant formula, Rye says. They approached us and said, Listen, youve got something really interesting: if you can make human milk, you can transform the way infant formula is done. We realised, this is where the demand is. Its also where the big money is: customers are used to paying a lot more for infant formula than they are for cows milk.

Instead of producing and bottling its own breast milk, TurtleTree Labs plans to licence its technology to existing formula companies. Rye wont tell me the names, only that they are four of the five biggest in the world.

There are huge regulatory hurdles to be crossed before lab-grown breast milk can go on sale, but Rye and Lin say getting approval for its individual components will be more straightforward. And they are thinking very broadly about possible consumers: elderly people and cancer patients may one day drink their breast milk or parts of it.

Early indications show certain bioactive proteins or complex sugars in human milk could be good for senior care and adult health, Lin says. Geriatric patients can have similar issues with their digestive system as infants, and early studies have shown certain compounds in breast milk may impede the growth of some cancers. But the benefits are under-researched: there isnt enough spare human milk to be giving it to adults on a clinically significant scale, and convincing them to try it is a challenge.

As soon as those sugars and proteins get regulatory approval, though, they can be added to existing infant formulas bringing them closer to breast milk than ever. TurtleTree expect that to happen as early as next year.

***

Strickland balks at the idea of working with the formula industry. Theres already distrust of these companies, the Nestls and Abbotts of the world, she says. We think its important to bring this product to market with as much credibility and authenticity as possible, as women and mothers and scientists ourselves. Our customers will appreciate seeing it come from us, rather than them.

Biomilqs initial plan is as eye-catching as the product itself: they are going to produce customised breast milk for early adopters, grown from the customers own cells. Moms would go through a fine needle biopsy procedure during their pregnancy, Strickland explains. That cell sample would be sent to us so we could start growing it up and producing milk. And then when shes ready, we can start shipping it to her.

I wasnt expecting to hear this: taking cells from pregnant women suggests that Biomilq is not solely for women who are having trouble breastfeeding but is also geared to those who assume they will need help before their baby even arrives. And its going to be very expensive, Strickland says: That would go at a pretty high price point, as a custom service.

But the initiative is more about demonstrating the potential of the product than the beginning of a business model, she says. We aim to generate an evangelised group of moms, parents and caregivers, who are excited enough to make that initial level of commitment.

It is difficult to envisage a way that breast milk grown in a lab can be anything other than an elite product. TurtleTree Labs estimates their milk costs $30 (23) a litre to produce, and even if that figure comes down dramatically (as they expect it to), the technology involved will always be more expensive than dairy-based formula. While breastfeeding is free, it is rarely compatible with full-time employment. A product like this will give those who can afford it either a nutritional edge, or a professional one.

Isnt this just going to be for very wealthy women? And wont it give them even greater advantages than they already enjoy?

We do not want this to be a product that perpetuates inequalities, Strickland replies, firmly. Thats something we think a lot about. Making this widely accessible is very much a part of our long-term plan. For instance, Biomilq is exploring ways employers might be able to subsidise the product for their staff although this raises further concerns that employers might expect nursing mothers to return to work earlier. Its a bit like a game of whack-a-mole: you push down on one problem and something pops up on the other side, Strickland concedes.

It may be many years before we can go to the supermarket and buy a bottle of breast milk. But the existence of companies such as TurtleTree Labs and Biomilq could well be a symptom of a problem, rather than a solution. In the wrong circumstances, their products could be used to stop women from breastfeeding in public, or to make formula feeding even more taboo. If women were more supported in breastfeeding, less ashamed of using the good enough dairy-based formula and less judged in general, then breast milk grown in a lab might not be necessary.

Strickland thinks once her product is on the market, it will be less easy to judge women for how they feed their babies. A mom sitting there feeding a bottle of our milk will look the same as a mother with a bottle of formula or her pumped milk. It would be indistinguishable, she says. Plus lab-grown milk is already provoking much-needed discussions about what we think is natural. If nothing else, I consider Biomilq already a success because we get to participate in these conversations.

Its hard to argue with that. But whether lab-grown breast milk changes the conversation for the better depends on who is making it, and who gets to use it. This invention may be Stricklands baby, but she cant control what it will grow into.

Jenny Kleeman is the author of Sex Robots & Vegan Meat: Adventures At The Frontier Of Birth, Food, Sex & Death (Picador).

Read more:
I want to give my child the best: the race to grow human breast milk in a lab - The Guardian

Insights on the Glycobiology Global Market to 2025 – Featuring Shimadzu, Takara Bio & Waters Among Others – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Global Glycobiology Market By Type of Enzyme (Glycosidases & Neuramidases, Glycosyltransferases & Sialytransferases, Carbohydrate kinases, Carbohydrate Sulfotransferases, Others), By Type of Kit, By Application, By End User, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Glycobiology Market is expected to grow at a formidable rate during the forecast period. The Global Glycobiology Market is driven by the growing prevalence of chronic diseases such as cancer, diabetics, renal diseases, among others, which has increased the demand for personalized medicines.

This in turn has increased the drug discovery process around the globe, which is anticipated to positively impact growth of the market during the forecast period. Also, increasing grants by different governments especially in the developing nations for R&D activities is further expected to bolster the growth of the market over the next few years.

The Global Glycobiology Market is segmented based on type of enzyme, type of kit, application, end-user, company and region. Based on type of enzyme, the market can be categorized into glycosidases & neuramidases, glycosyltransferases & sialytransferases, carbohydrate kinases, carbohydrate sulfotransferases, protein sulfotransferases and others. The glycosidases & neuramidases segment is expected to dominate the market during the forecast period. This can be ascribed to their pivotal role in metabolism, antibacterial defense & pathogenesis, glycosidase probe design for ABPP represents an important task in chemical proteomic & glycomic research.

Regionally, the glycobiology market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these, North America is expected to witness significant growth during the forecast period in the overall glycobiology market owing to the presence of many research laboratories and pharmaceutical and biotechnology companies in the region.

Companies Mentioned

Objective of the Study:

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Glycobiology Market

4. Executive Summary

5. Voice of Customer

5.1. Brand Awareness (Aided/Unaided)

5.2. Product Awareness

5.3. Customer Satisfaction Analysis

5.4. Unmet Needs/Challenges

6. Global Glycobiology Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type of Enzyme (Glycosidases & Neuramidases, Glycosyltransferases & Sialytransferases, Carbohydrate Kinases, Carbohydrate Sulfotransferases, Protein Sulfotransferases, Others)

6.2.2. By Type of Kit (Glycan Releasing Kit, Glycan Labelling Kit, Glycan Purification Kit, Others)

6.2.3. By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others)

6.2.4. By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others)

6.2.5. By Company (2019)

6.2.6. By Region

6.3. Product Market Map

7. Asia-Pacific Glycobiology Market Outlook

8. Europe Glycobiology Market Outlook

9. North America Glycobiology Market Outlook

10. South America Glycobiology Market Outlook

11. Middle East and Africa Glycobiology Market Outlook

12. Market Dynamics

12.1. Drivers

12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

15. Strategic Recommendations

16. About Us & Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/vjs9ex

Visit link:
Insights on the Glycobiology Global Market to 2025 - Featuring Shimadzu, Takara Bio & Waters Among Others - ResearchAndMarkets.com - Business Wire

Study sheds new light on the immune system response to COVID-19 – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Nov 16 2020

A team of immunology experts from research organizations in Belgium and the UK has come together to apply their pioneering research methods to put individuals' COVID-19 responses under the microscope.

Published today in the journal Clinical and Translational Immunology, their research adds to the developing picture of the immune system response and our understanding of the immunological features associated with the development of severe and life-threatening disease following COVID-19.

This understanding is crucial to guide the development of effective healthcare and 'early-warning' systems to identify and treat those at risk of a severe response.

One of the most puzzling questions about the global COVID-19 pandemic is why individuals show such a diverse response. Some people don't show any symptoms, termed 'silent spreaders', whereas some COVID-19 patients require intensive care support as their immune response becomes extreme.

Age and underlying health conditions are known to increase the risk of a severe response but the underlying reasons for the hyperactive immune response seen in some individuals are unexplained, although likely to be due to many factors contributing together.

To investigate the immune system variations that might explain the spectrum of responses, teams of researchers from the VIB Centre for Brain and Disease Research and KU Leuven in Belgium and the Babraham Institute in the UK worked with members of the CONTAGIOUS consortium to compare the immune system response to COVID-19 in patients showing mild-moderate or severe effects, using healthy individuals as a control group.

One of our main motivations for undertaking this research was to understand the complexities of the immune system response occurring in COVID-19 and identify what the hallmarks of severe illness are. We believe that the open sharing of data is key to beating this challenge and so established this data set to allow others to probe and analyze the data independently."

Adrian Liston, Professor and Senior Group Leader, Babraham Institute

The researchers specifically looked at the presence of T cells - immune cells with a diverse set of functions depending on their sub-type, with 'cytotoxic' T cells able to kill virus-infected cells directly, while other 'helper' T cell types modulate the action of other immune cells.

The researchers used flow cytometry to separate out the cells of interest from the participants' blood, based on T cell identification markers, cell activation markers, and cytokine cell signaling molecules.

Surprisingly, the T cell response in the blood of COVID-19 patients classified as severe showed few differences when compared to healthy volunteers. This is in contrast to what would usually be seen after a viral infection, such as the 'flu.

However, the researchers identified an increase in T cells producing a suppressor of cell inflammation called interleukin 10 (IL-10). IL-10 production is a hallmark of activated regulatory T cells present in tissues such as the lungs. While rare in healthy individuals, the researchers were able to detect a large increase in the number of these cells in severe COVID-19 patients.

Potentially, monitoring the level of IL-10 could provide a warning light of disease progression, but the researchers state that larger-scale studies are required to confirm these findings.

"We've made progress in identifying the differences between a helpful and harmful immune response in COVID-19 patients. The way forward requires an expanded study, looking at much larger numbers of patients, and also a longitudinal study, following up patients after an illness. This work is already underway, and the data will be available within months," says Professor Stephanie Humblet-Baron, at the KU Leuven in Belgium.

"This is part of an unprecedented push to understand the immunology of COVID-19", concludes Professor Liston. "Our understanding of the immunology of this infection has progressed faster than for any other virus in human history - and it is making a real difference in treatment. Clinical strategies, such as switching to dexamethasone, have arisen from a better understanding of the immune pathology of the virus, and survival rates are increasing because of it".

Source:

Journal reference:

Neumann, J., et al. (2020) Increased IL10producing regulatory T cells are characteristic of severe cases of COVID19. Clinical & Translational Immunology. doi.org/10.1002/cti2.1204

Read more:
Study sheds new light on the immune system response to COVID-19 - News-Medical.Net